Market closed
Gain Therapeutics/$GANX
Gain Therapeutics shares are trading higher after the company reported its Q1 results.
20 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gain Therapeutics
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
Ticker
$GANX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
24
ISIN
US36269B1052
Website
GANX Metrics
BasicAdvanced
$50M
-
-$0.82
-
-
Price and volume
Market cap
$50M
52-week high
$2.53
52-week low
$1.48
Average daily volume
303K
Financial strength
Current ratio
2.218
Quick ratio
1.853
Long term debt to equity
5.97
Total debt to equity
10.5
Management effectiveness
Return on assets (TTM)
-97.09%
Return on equity (TTM)
-290.21%
Valuation
Price to book
9
Price to tangible book (TTM)
9.2
Price to free cash flow (TTM)
-2.418
Growth
Earnings per share change (TTM)
-43.44%
3-year earnings per share growth (CAGR)
-12.62%
GANX News
AllArticlesVideos
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
GlobeNewsWire·3 days ago
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders
GlobeNewsWire·5 days ago
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Gain Therapeutics stock?
Gain Therapeutics (GANX) has a market cap of $50M as of May 17, 2025.
What is the P/E ratio for Gain Therapeutics stock?
The price to earnings (P/E) ratio for Gain Therapeutics (GANX) stock is 0 as of May 17, 2025.
Does Gain Therapeutics stock pay dividends?
No, Gain Therapeutics (GANX) stock does not pay dividends to its shareholders as of May 17, 2025.
When is the next Gain Therapeutics dividend payment date?
Gain Therapeutics (GANX) stock does not pay dividends to its shareholders.
What is the beta indicator for Gain Therapeutics?
Gain Therapeutics (GANX) does not currently have a Beta indicator.